Global Markets for Blood Plasma Products

NEW YORK, Aug. 1, 2017 /PRNewswire/ --

-- The global market for blood plasma reached $16.8 billion in 2016 and should reach $23.0 billion in 2021, growing at a compound annual growth rate (CAGR) of 6.6% from 2016 through 2021.

Read the full report:

-- North America market for blood plasma reached $8.2 billion in 2016 and should reach $11.1 billion in 2021, growing at a CAGR of 6.3% from 2016 through 2021.
-- Asia-Pacific market for blood plasma reached $4.4 billion in 2016and should reach $6.1 billion in 2021, growing at a CAGR of 7.1% from 2016 through 2021.

Study Goals and Objectives
-- Define as well as identify key segments and market structure in blood plasma technologies.
-- Estimate and measure the global blood plasma market and its segments, including applications, product categories, end users, modes of product delivery and geographic segmentation.
-- Identify key market dynamics and factors impacting the global blood plasma market and its subsegments.
-- Identify trends, gaps and opportunities in each micromarket.
-- Focus exclusively on geographic segmentation by analyzing trends and opportunities in North America, Europe, Asia and the Rest of the World (RoW).
-- Identify major stakeholders, product portfolios and recent developments and draw a competitive landscape for market leaders.

Reasons for Doing This Study
Plasma, the largest component of blood, accounts for 55% of total blood composition. Plasma consists of various components such as water, electrolytes, albumin, immunoglobulins and more. Each component of blood plasma performs a different function in the body and all play vital roles in ensuring performance.

Additionally, plasma serves as a carrier for nutrients and hormones as well as the proteins that transport these components throughout the body. Blood plasma is a major source of immunoglobulins and is used in the treatment of patients suffering from immunoglobulin deficiency.

Exploring the potential of blood plasma in the large-scale treatment of immunocompromised patients becomes essential with emerging incidences of primary as well as secondary immunodeficiencies. An increase in cases of hemophilia A, hemophilia B, von Willebrand disease and other bleeding disorders has resulted in a better understanding of blood plasma and the potential of blood plasma therapies in chronic disease management.

Scope of Report
This research report presents an in-depth analysis of the global blood plasma market by application, product category, mode of delivery, end user and geographic market. The report includes key blood plasma products used in various therapeutic treatments as well as an examination of the supply chain from research to manufacturing.

The report also features an in-depth analysis of key companies operating in the global blood plasma market and patents that highlight past, current and projected global technology trends.

The blood plasma market is primarily segmented into five major blood plasma components: immunoglobulin, albumin, hyperimmunes, coagulation factors, and other plasma fractionation products. Immunoglobulins are further segmented into intravenous immunoglobulins, subcutaneous immunoglobulins and normal immunoglobulins such as immunoglobulin A (IgA), immunoglobin D (IgD), immunoglobin E (IgE), immunoglobin G (IgG), and immunoglobin M (IgM).

The global blood plasma market is further segmented by application which helps in understanding the potency of blood plasma products in several therapeutic treatments. Products based on these applications are explored in detail and their influence on R&D is examined. The market is segmented by geography into North America, Europe, Asia-Pacific and RoW. Companies profiled in this report include Grifols S. A., Octopharma AG, Biotest AG, Shire, CSL Ltd., Kedrion S.p.A., China Biologic Products, Sanquin, and others.

Information Sources and Methodology
The report covers all revenue generated by sales of blood plasma derivatives. Blood plasma and its components are employed in the treatment of various diseases. Blood plasma therapies are essentially used in the treatment of hemophilia A, hemophilia B and leukemia. Blood plasma derivative products are available in a wide variety of forms based on the therapy used.

The report also examines:
-- Revenue generated by the sales of products that are a result of blood plasma fractionation and are used in blood plasma therapies. These products include individual components such as albumin and IVIG among others.
-- Revenue generated by manufacturers from products used by healthcare providers who also charge service costs (these service costs are not considered in this report).
-- Revenue generated by laboratories and manufacturers for treatments carried out by government agencies, insurers or employers (in which the individual being tested does not pay for test) in such cases revenues paid by the government or insurers to the manufacturers is considered.
-- Advisory and/or counseling costs associated with treatment provided to the patients by doctors, nurses or other healthcare individuals is not considered in the report.

Intended Audience
-- Manufacturers of blood plasma products and potential entrants to the market.
-- Dealers, distributors and service providers of blood plasma products and therapies.
-- Research institutes, associations and academicians.

Geographic Breakdown
North America
-- U.S.
-- Mexico
-- Canada

-- U.K.
-- France
-- Germany
-- Rest of Europe

-- Australia
-- China
-- Japan
-- India
-- Rest of Asia-Pacific

Rest of the world (RoW)
-- Central and South America
-- The Middle East
-- Africa

Summary and Highlights
Plasma, the major component of blood, is vital to the regulation of body functions. Blood plasma consists of several useful components such as albumin, coagulation factors, protease inhibitors and immunoglobulins.

Since deficiencies in a component can result in the onset of a disease, both basic and targeted R&D has accelerated in this area. Blood plasma is part of an effective therapeutic treatment plan in various therapies due to its potential in battling several chronic and life-threatening diseases such as hemophilia, leukemia, immunodeficiencies and other bleeding diseases. Blood plasma products have proven to be a boon for patients suffering from such diseases which has necessitated a more in- depth understanding of their application.

Of all the components of plasma, immunoglobulins are the most widely used in the treatment of various diseases and rising demand for them is the main driver of the global blood plasma market.

Immunoglobulins play a crucial role in the treatment of immunocompromised patients.

Immunodeficiency, the major factor responsible for severe infections in such patients, is a significant concern in various regions of the world and is expected to drive growth. New product launches and improvements in existing technologies are increasing demand for blood plasma products on the global market.

However, two major restraining factors are the high costs associated with these therapies along with the threat of transmission of blood-borne diseases. Ensuring safety as well as efficacy during blood donations and transfusions will aid in overcoming this threat.

In this report, the global blood plasma market is studied through different perspectives including product application, end user consumption, and global market analysis.

The blood plasma market is categorized into five types: immunoglobulins, coagulation factor concentrates, albumin, hyperimmunes, and other plasma fractionation products. The immunoglobulin segment registered a revenue of nearly $8.1 billion in 2016 and is poised to grow at a CAGR of 7.0% throughout the forecast period.

The immunoglobulins segment is projected to attain revenue of $11.3 billion by 2021. Immunoglobulins have been in demand for the treatment of immunocompromised patients. Polyvalent immunoglobulins, in particular, have gained immense traction in recent years.

The market is segmented by application into the following categories: immunology, pulmonologist, oncology, rheumatology, neurology, hematology, transplants and other applications. Neurology has dominated the global blood plasma market and this trend is expected to continue during the forecast period.

This segment accounted for revenue of $6.4 billion in 2016 at a CAGR of 6.6% and, by 2021, is anticipated to reach $8.7 billion. The use of blood plasma products in pulmonary applications has increased in recent years at a CAGR of 7.3% which indicates rapid growth. Blood plasma is utilized in the treatment of pulmonary hemorrhage and as a potential marker for various pulmonary conditions.

The market is split into three end user segments: hospitals and clinics, research laboratories, and academic institutions. Hospitals and clinics dominate the global blood plasma market, accounting for revenue of $13.9 billion. Revenue is anticipated to reach $20.1 billion by 2021 at a CAGR of 6.4%.

By geography, the market is categorized into four regions: North America, Europe, Asia-Pacific and Rest of World. North America held the largest market share in 2016, accounting for nearly $8.2 billion at a CAGR of 6.3% during the forecast period and is expected to total $11.1 billion by 2021. The U.S. leads the market due to surging demand for blood plasma products and therapies for hemophilic patients.

Asia-Pacific held the second largest market share, accounting for $4.3 billion in 2016 and $6.1 billion in revenue is expected by 2021 at a CAGR of 7.1%. China leads the market in the Asia-Pacific region with growth supplemented by increasing government initiatives to encourage blood plasma donation and to maintain supplies throughout the region. Asia-Pacific is a lucrative market for blood plasma products and the majority of markets in both the Asia-Pacific and RoW regions are untapped and will provide opportunities for manufacturers to expand.

The European market accounted for $3.7 billion in 2016 and is expected to reach $5.1 billion by 2021 at a CAGR of 6.5%. Rest of world (RoW) which includes Latin America, the Middle East and Africa, accounted for $447 million in revenue and is expected to reach
$624 million by 2021 at a CAGR of 6.9%.

Based on patent analyses for the years 2014 to 2017, the greatest number of patents were registered by China due to its extensive focus on R&D and innovation facilities. Additionally, China has adopted several different plasma fractionation technologies to ensure sufficient blood plasma supply throughout the region which also contributes to the country's lucrative market for products and therapies.

Key players driving this market through extensive R&D across all geographies include CSL Ltd., Kedrion S.p.A., Grifols S.A., Biotest AG, Shire, Sanquin, China Biologic Products, Octopharma AG, among others.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:

SOURCE Reportlinker